Maze Therapeutics to present Phase 2 HORIZON data for MZE829 in APOL1-mediated kidney disease at ASN Kidney Week 2026
Bitget2026/10/06 20:07Maze Therapeutics flagged upcoming presentations on its kidney pipeline at ASN Kidney Week on Oct. 21-25, 2026. Previously reported Phase 2 HORIZON results for MZE829 in APOL1-mediated kidney disease will be presented again with added detail. The update pointed to encouraging clinical activity, supporting continued development of the lead program. Separate preclinical work on MZE782 is set to be shown, backing SLC6A19 inhibition as a potential approach in chronic kidney disease. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610061605PRIMZONEFULLFEED9840861) on October 06, 2026, and is solely responsible for the information contained therein.
- Maze Therapeutics flagged upcoming presentations on its kidney pipeline at ASN Kidney Week on Oct. 21-25, 2026.
- Previously reported Phase 2 HORIZON results for MZE829 in APOL1-mediated kidney disease will be presented again with added detail.
- The update pointed to encouraging clinical activity, supporting continued development of the lead program.
- Separate preclinical work on MZE782 is set to be shown, backing SLC6A19 inhibition as a potential approach in chronic kidney disease.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
